Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to develop a more physiological approach to the management of children and adolescents with salt wasting Congenital Adrenal Hyperplasia.

We will administer the glucocorticosteroid via insulin infusion pump to see whether this treatment will improve the serum hormone concentrations.


Clinical Trial Description

The adrenal gland is a small organ of the body. It produces very important chemicals called hormones. One of these hormones, cortisol (the stress hormone) helps the body fight diseases. The other hormone is the aldosterone helps to maintain the normal amount of salt and water in the body. The third type of hormones are the androgens or male hormones, which cause some of the changes during puberty, like the growth of body hair and pimples.

The salt wasting Congenital Adrenal Hyperplasia or CAH disease is a disease of the adrenal gland. Patients with this disease cannot make cortisol or the aldosterone. As a result, their body cannot fight diseases and cannot keep normal amounts of salt and water in the body. At the same time, the gland makes too much of the male hormones, which is bad for the body because too much male hormone slows down growth, increases the growth of body hair, and causes pimples and abnormal period in girls.

Patients with this disease have to take medications every day. However, the treatment does not work very well, because usually the patients do not have the right amount of hormone in their body. Usually the body gets too much hormone right after taking the pills. A couple of hours later the body has too little of the hormones, because in the meantime the body gets rid of the medication.The healthy adrenal gland makes the hormones throughout the day in different amounts. The patients with this disease take the medication only a couple of times a day. They take the Florinef tablet once a day and the Cortisol tablet two or three times a day. The treatment that we use today by mouth cannot copy the natural hormone productions of the adrenal gland. Because of this it does not make much of a difference in the patient's life.

We would like to improve the treatment and find out the effect of a new treatment. In this study we will try to imitate the body's normal hormone production and will give the medication via an insulin pump to see if this treatment method will decrease the male hormones in the blood. This study will help us to develop a new and better treatment for children and adolescents. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00529841
Study type Interventional
Source Baylor College of Medicine
Contact
Status Completed
Phase N/A
Start date January 2007
Completion date September 2008

See also
  Status Clinical Trial Phase
Completed NCT03162172 - Growth Hormone (GH) in Congenital Adrenal Hyperplasia N/A
Recruiting NCT00617292 - Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers N/A
Recruiting NCT05228652 - Questionnaire Study to Assess the Outcomes of the Management of Congenital Adrenal Hyperplasia Individuals
Recruiting NCT01771328 - Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia Phase 2
Active, not recruiting NCT01862380 - Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency. N/A
Completed NCT03589144 - LC-MS / MS Adrenal Steroids Assayed on Dried Blot Spot for the Congenital Adrenal Hyperplasia Neonatal Screening (SPECTROSPOT)
Completed NCT01488721 - Clinical Evaluation of NeoPlex4 Assay and NeoPlex System N/A
Recruiting NCT00694525 - Role of the Protein Osteoprotegerin in the Bone Health of Women With Congenital Adrenal Hyperplasia N/A
Completed NCT00621985 - Dexamethasone Treatment of Congenital Adrenal Hyperplasia Phase 2